Roche deal spurs merger and acquisition activity across the biotech industry.

Drug giant Roche is buying biotech firm InterMune for $8.3 billion. CNBC's Jim Cramer discusses the lifesaving drug behind the wave of M&A deals.

The Swiss Pharmaceutical Giant, Roche, has agreed to acquire InterMune Inc. for $8.3 billion in cash. InterMune (NASDAQ: ITMN) is a biopharmaceutical company, based in Brisbane California, specializing in the development and commercialization of medicine to treat fibrotic lung diseases.

The market has been confused regarding Mannkind's recent partnership with Sanofi to commercialize the company's lead drug, Afrezza. However, the deal is quite favorable under 360's integrated analysis.

As there have been some confusions regarding Mannkind's recent commercial partnership with Sanofi in launching it's lead drug Afrezza, the super rapid acting insulin, as early as in the first quarter of 2015.

InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the second quarter ended June 30, 2014. The company also highlighted recent clinical development and business highlights, and updated its forward-looking financial guidance for 2014.